Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
European Green Transition plc (AIM: EGT) Result of fundraise via placing and subscription
European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces that, further to its announcement
European Green Transition plc (AIM: EGT) Acquisition of infrastructure services platform
EGT has shared some very exciting news this morning as we have signed a binding share purchase agreement to acquire an established EBITDA profitable onshore wind turbine operating, maintenance, repairing
Poolbeg Pharma (AIM: POLB) POLB 001 LPS Challenge Trial Paper Published
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
Six Biotechs to Watch in 2026: Breakthroughs, Setbacks, and Big Turning Points Ahead
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
10 Companies to Watch in 2026
2025 was the year AIM showed its resilience, rising nearly 10pc after enduring years of higher interest rates in the wake of the pandemic and continued economic and geopolitical uncertainty.
Six Biotechs to Watch in 2026: Breakthroughs, Setbacks, and Big Turning Points Ahead
The biotechnology market has delivered a mixed landscape in 2025, shaped by shifting investor sentiment, ongoing regulatory pressures, and the continued search for differentiated clinical assets. Against this backdrop several
Poolbeg Pharma (AIM: POLB) Letter to Shareholders – 2025 a year of progress
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected
Poolbeg Pharma (AIM: POLB) POLB 001 to feature in CRS research programme
POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part
Poolbeg Pharma (AIM: POLB) secures European patent for POLB 001
Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II